Skip to content

Home
Artificial intelligence
Biotechnology
Genetics
Medical Technology

Home
Uncategorized
Galecto appoints former Blueprint Medicines executives as COO and CMO

Galecto appoints former Blueprint Medicines executives as COO and CMO

Jan 6, 2026

Post navigation

Dark Blue Therapeutics acquired by Amgen for up to $840 million

Lung Cancer Research Foundation Announces Additional 2025 Scientific Research Grant Awards

PR Newswire
GlobeNewswire

Contact
Privacy Policy

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Search for: